Skip to main content
PegBio Co., Ltd. logo

PegBio Co., Ltd. — Investor Relations & Filings

Ticker · 2565 HKEX Professional, scientific and technical activities
Open in API
Filings indexed 2,123 across all filing types
Latest filing 2025-10-24 Board/Management Inform…
Country HK Hong Kong
Listing HKEX 2565

About PegBio Co., Ltd.

http://www.pegbio.com

PegBio Co., Ltd. is a biotechnology company specializing in the in-house discovery and development of innovative therapies for chronic diseases, primarily focusing on the endocrine and metabolic fields. The company leverages its proprietary HECTORTM technology system to design and screen novel molecular entities, including peptide, protein, and small-molecule drugs, targeting unmet clinical needs. PegBio's robust pipeline addresses major chronic conditions such as Type 2 Diabetes (T2DM), obesity, and metabolic dysfunction-associated steatohepatitis (MASH). Key pipeline assets include long-acting GLP-1 receptor agonists, such as Vepinatide, developed for T2DM treatment and weight management. The company emphasizes creating complementary, multi-benefit product pipelines characterized by new targets, new sites, and new mechanisms of action.

Recent filings

Filing Released Lang Actions
RESIGNATION OF EXECUTIVE DIRECTOR, DEPUTY GENERAL MANAGER AND MEMBER OF BOARD COMMITTEES
Board/Management Information Classification · 1% confidence The document is an official announcement by CMBC Capital Holdings Limited regarding the resignation of an executive Director and deputy general manager, including cessation of board committee memberships. It outlines changes in board composition and contains no financial results, proxy materials, or regulatory form references. This fits the definition of a Board/Management Information filing (MANG).
2025-10-24 English
VOLUNTARY ANNOUNCEMENT - PROPOSED GRANT OF AN EXCLUSIVE LICENSE FOR VISEPEGENATIDE (PB-119) IN THE MIDDLE EAST AND AFRICA
Regulatory Filings Classification · 1% confidence The document is a voluntary announcement by PegBio Co., Ltd. regarding a proposed exclusive licensing agreement for its product PB-119 in the Middle East and Africa. It is not an annual or interim report, earnings release, management change notice, dividend announcement, M&A bid, share issuance, or any other specific category. It is a general corporate announcement of a licensing transaction. Therefore, it does not fit a specialized category and is best classified under the fallback “Regulatory Filings” (RNS).
2025-10-10 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 September 2025
Share Issue/Capital Change Classification · 1% confidence The document is HKEX Form FF301, a mandatory monthly return detailing movements in registered share capital, issued shares, and treasury shares under the Exchange Listing Rules. It is not announcing an AGM, earnings, or financial statements but specifically discloses share capital changes (even though no changes occurred this reporting month). Under our taxonomy, announcements of share capital changes—including new issues, repurchases, or other capital structure movements—fall under Share Issue/Capital Change (SHA).
2025-10-06 English
MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED 30 SEPTEMBER 2025
Regulatory Filings Classification · 1% confidence The document is a standardized HKEX monthly return (Form FF301) detailing movements in authorised/registered share capital, issued shares, treasury shares, and other share-related arrangements for the month ended 30 September 2025. It is a regulatory compliance filing to the Exchange rather than an earnings release, management discussion, financing update, share issue announcement, or other specific event report. It does not constitute an Annual or Interim Report, nor a capital raising announcement, dividend notice, proxy statement, or share repurchase notice. Therefore, it falls into the general regulatory filings category (RNS).
2025-10-02 English
2025 Interim Report
Interim / Quarterly Report Classification · 1% confidence The document is explicitly titled '2025 Interim Report' (中期報告) for PegBio Co., Ltd. It contains comprehensive financial statements (Consolidated Statement of Profit or Loss, Financial Position, Changes in Equity, Cash Flows), notes to the unaudited interim financial report, and a detailed Management Discussion & Analysis (MDA) section. It covers the six-month period ended June 30, 2025. This meets the criteria for an Interim/Quarterly Report (IR) as it provides substantive financial data and analysis for a period shorter than a full fiscal year. H1 2025
2025-09-29 English
DISCLOSEABLE TRANSACTION IN RELATION TO ACQUISITION OF CONVERTIBLE SECURITIES
Capital/Financing Update Classification · 1% confidence The document is a Hong Kong Stock Exchange announcement by CMBC Capital Holdings about a discloseable transaction under the Listing Rules—the acquisition of US$20 million in Barclays convertible securities. It is neither an earnings release, management discussion, nor an AGM/board change, and does not involve issuing the company’s own shares. Rather, it details a capital/financing activity (i.e. acquisition of debt-like securities). Hence it falls under Capital/Financing Update (CAP).
2025-09-25 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.